Confirm sterile urine culture prior to procedure. Obtain baseline ultrasound of the renal tract. Patient must remain NPO (nothing by mouth) for at least 4 hours before the procedure. Ensure signed informed consent is obtained.
Patient is monitored for 1-2 hours until alert and able to void. Ensure patient has no fever or severe dysuria before discharge. Standard post-operative antibiotics are administered if indicated. Resume normal activity within 24 hours. Follow-up renal ultrasound scheduled at 3 months.
Clinical Guide: Endoscopic Deflux Injection for Vesicoureteral Reflux (VUR)
1. Introduction and Overview
Vesicoureteral Reflux (VUR) is a common urological condition in the pediatric population, characterized by the retrograde flow of urine from the bladder into the ureters and potentially the kidneys. If left untreated, chronic VUR can lead to recurrent febrile urinary tract infections (UTIs), renal scarring, hypertension, and, in severe cases, end-stage renal disease (ESRD).
Endoscopic subureteral injection of bulking agents has revolutionized the management of VUR, shifting the clinical paradigm from chronic antibiotic prophylaxis or invasive open ureteral reimplantation to a minimally invasive, day-case surgical intervention. Deflux, a biocompatible gel composed of non-animal stabilized hyaluronic acid (NASHA) and dextranomer microspheres, serves as the gold standard for this procedure. This guide provides a comprehensive clinical overview for medical professionals regarding the utilization of Deflux in the management of VUR.
2. Technical Specifications and Mechanism of Action
The Science of Deflux
Deflux consists of two primary components suspended in a phosphate-buffered saline carrier:
* Dextranomer Microspheres: These provide long-term stability and act as a scaffold for tissue ingrowth.
* Non-Animal Stabilized Hyaluronic Acid (NASHA): This serves as the carrier to facilitate injection and provides immediate volume, which is subsequently replaced by the patient’s own collagen and fibroblasts over time.
Mechanism of Action
The therapeutic goal is to restore the competence of the vesicoureteral junction (VUJ). By injecting the bulking agent into the submucosal space of the distal ureter, the surgeon creates a "bolus" that:
1. Coapts the ureteral orifice.
2. Increases the length of the intravesical ureteral tunnel.
3. Prevents the retrograde flow of urine during bladder filling and voiding.
3. Clinical Indications and Patient Selection
Indications
The primary candidates for Deflux injection are pediatric patients diagnosed with primary VUR. Indications include:
* Grades II–IV VUR: Patients who have experienced breakthrough UTIs while on prophylactic antibiotics.
* Non-compliance: Patients or families unable or unwilling to adhere to long-term antibiotic prophylaxis.
* Resolution Failure: Patients who have not shown spontaneous resolution of VUR after an appropriate period of observation.
* Anatomical Considerations: Patients with duplication anomalies where the lower pole ureter exhibits reflux.
Contraindications
- Grade V VUR: While sometimes attempted, success rates are significantly lower; open surgery is generally preferred.
- Active UTI: The procedure must be deferred until the urine is sterile.
- Neurogenic Bladder: Patients with severe bladder dysfunction (e.g., myelomeningocele) may require prior management of bladder dynamics before considering endoscopic intervention.
- Large Para-ureteral Diverticula: These anatomical anomalies prevent the formation of a stable submucosal tunnel.
4. Pre-Operative Preparation
Success in endoscopic management relies heavily on precise pre-operative assessment:
* Imaging: A recent Voiding Cystourethrogram (VCUG) is mandatory to grade the reflux. A renal ultrasound is required to assess for pre-existing scarring or hydronephrosis.
* Urodynamic Assessment: In children with suspected voiding dysfunction, uroflowmetry or formal urodynamics should be performed.
* Antibiotic Coverage: A single dose of prophylactic antibiotics is typically administered at the induction of anesthesia.
* Anesthesia: The procedure is performed under general anesthesia with a laryngeal mask or endotracheal intubation.
5. The Procedure: Step-by-Step Intervention
The procedure is performed cystoscopically, typically utilizing the HIT (Hydrodistention Implantation Technique) or the Double-HIT for larger orifices.
| Step | Action Description |
|---|---|
| Cystoscopy | Insertion of a pediatric cystoscope to visualize the bladder neck and ureteral orifices. |
| Assessment | Examination of the orifice shape (e.g., "golf-hole" vs. "slit") and the quality of the submucosal tunnel. |
| Needle Placement | The injection needle is introduced into the submucosal space, approximately 3–4 mm distal to the orifice at the 6 o'clock position. |
| Injection | The Deflux is injected slowly. A "hump" or bulge must be clearly visible, elevating the floor of the ureter. |
| Coaptation | The goal is to achieve total coaptation of the ureteral orifice, causing the lips of the orifice to touch. |
| Withdrawal | The needle is removed slowly, and a final check of the "bulge" stability is performed. |
6. Post-Operative Recovery Protocol
The beauty of the Deflux procedure lies in its rapid recovery profile:
* Immediate Post-Op: Monitoring in the PACU for voiding. Most patients are discharged within 2–4 hours.
* Pain Management: Usually managed with simple analgesics (acetaminophen or ibuprofen).
* Antibiotics: Surgeons may choose to continue low-dose prophylaxis for 4–6 weeks post-procedure, though this is institutional preference.
* Follow-up: An ultrasound is typically performed at 3 months post-op to assess for ureteral obstruction or hydronephrosis. A follow-up VCUG is typically scheduled at 6–12 months to confirm the resolution of reflux.
7. Outcomes and Complications
Clinical Outcomes
- Success Rates: Meta-analyses indicate a success rate of approximately 75–85% after a single injection.
- Repeatability: If reflux persists, a second injection has a high success rate (approx. 70%).
- Durability: Data shows that the bulking effect remains stable over years; long-term recurrence of VUR is rare once the initial success is confirmed.
Potential Complications
| Complication | Mitigation Strategy |
|---|---|
| Ureteral Obstruction | Avoid over-injection; ensure the ureteral lumen remains patent. |
| UTI | Adherence to sterile technique and antibiotic prophylaxis. |
| Migration | Rare; use of high-quality, stable NASHA-based agents minimizes this risk. |
| Hematuria | Usually self-limiting; monitor fluid intake post-op. |
8. Alternative Treatments
- Observation/Antibiotic Prophylaxis: Conservative management remains the first-line for Grade I/II reflux, which carries a high spontaneous resolution rate.
- Open Ureteral Reimplantation (Cohen Procedure): The gold standard for high-grade (Grade V) VUR or failed endoscopic injections. Highly effective but invasive with a longer hospital stay.
- Laparoscopic/Robotic Reimplantation: Offers the success of open surgery with the aesthetic and recovery benefits of minimally invasive surgery.
9. Frequently Asked Questions (FAQ)
1. Is Deflux permanent?
Yes, the dextranomer microspheres remain at the site, creating a permanent structural support, while the hyaluronic acid carrier is resorbed.
2. How long does the procedure take?
Typically, the procedure is completed in 15 to 30 minutes.
3. Is there a limit to how many times it can be injected?
Generally, up to two or three injections can be performed. If those fail, the anatomy may not be suitable for endoscopic correction, and open surgery is indicated.
4. Does the patient need a catheter after surgery?
In the vast majority of cases, no catheter is required.
5. What is the success rate for Grade IV VUR?
Success rates are lower than for Grade II/III, usually hovering around 60-70% for the first injection.
6. Can Deflux be used in adults?
While off-label, it is sometimes used in adults with persistent VUR, though outcomes are less robust than in children.
7. What are the signs of post-operative obstruction?
Signs include flank pain, fever, or vomiting. An ultrasound should be performed if these occur.
8. Is this procedure covered by insurance?
In most regions, Deflux injection is a recognized, standard-of-care procedure for VUR and is widely covered.
9. How soon can the child return to school?
Most children return to normal activities within 24–48 hours.
10. Are there any long-term risks with the material used?
Deflux has been used for over two decades with an excellent safety profile and no evidence of systemic toxicity or carcinogenicity.
10. Conclusion
Endoscopic Deflux injection represents a significant advancement in pediatric urology. By providing a minimally invasive, highly effective, and safe solution for VUR, it minimizes the psychological and physical burden of chronic antibiotic therapy and major surgery. Proper patient selection and meticulous surgical technique are the cornerstones of success in clinical practice.
Disclaimer: This guide is intended for medical professionals and is for informational purposes only. Clinical decisions should be based on institutional guidelines, patient-specific factors, and the judgment of the attending surgeon.